Technology areas: Biotechnology & Pharmaceuticals • Medical Devices & Mechanical Engineering
5 pending office actions • 5 art units • 5 examiners • 0 of 5 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Huyabio International LLC is currently managing 4 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are distributed across 4 distinct art units, which indicates that the company's filings span several specialized technical groups within the patent office. The prosecution involves 4 distinct examiners, meaning that every pending action is currently being reviewed by a different individual. This high ratio of examiners to actions suggests a broad and decentralized prosecution landscape for the company.
OUSPENSKI, ILIA I is designated as the busiest examiner for the portfolio, currently holding 1 busiest examiner pending office action. Although OUSPENSKI, ILIA I is the busiest, the 1 busiest examiner pending action represents only a portion of the 4 pending office actions total. The fact that 4 distinct examiners are involved across 4 distinct art units suggests that the company must manage multiple distinct examiner styles. This distribution of 4 pending office actions requires a coordinated effort to maintain consistency across the Biotechnology & Pharmaceuticals portfolio.
Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 3 (60%) |
| Double-patenting + other | 1 (20%) |
| Multi-statute (no §101) | 1 (20%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| OUSPENSKI, ILIA I | 1 | 77.3% | +20.6% |
| RAO, SAVITHA M | 1 | 60.7% | +29.7% |
| TOWNSLEY, SARA ELIZABETH | 1 | 25.6% | +48.2% |
| ELENISTE, PIERRE PAUL | 1 | 35.4% | +31.1% |
| BUTTICE, AUDREY L | 1 | 46.6% | +26.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18351439 | COMBINATION THERAPIES OF WDR-5 INHIBITORS AND PD-1 INHIBITORS | TOWNSLEY, SARA ELIZABETH | 22d overdue |
| 18120311 | MLL1-WDR5 PROTEIN-PROTEIN INTERACTION INHIBITOR COMPOUNDS AND USES THEREOF | ELENISTE, PIERRE PAUL | 8d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 16894532 | TRIPLET THERAPIES OF HDAC INHIBITORS, PD-L1 AND/OR PD-1 INHIBITORS, AND CTLA-4 INHIBITORS | BUTTICE, AUDREY L | 35d overdue |
| 18351439 | COMBINATION THERAPIES OF WDR-5 INHIBITORS AND PD-1 INHIBITORS | TOWNSLEY, SARA ELIZABETH | 22d overdue |
| 18120311 | MLL1-WDR5 PROTEIN-PROTEIN INTERACTION INHIBITOR COMPOUNDS AND USES THEREOF | ELENISTE, PIERRE PAUL | 8d |
| 18421171 | METHODS AND COMPOSITIONS COMPRISING A CARDIO-TOLERATED HDAC INHIBITOR | OUSPENSKI, ILIA I | — |
| 18517019 | Combination Therapies Comprising Kras Inhibitors and SPH2 Inhibitors | RAO, SAVITHA M | — |
| Art Unit | Apps |
|---|---|
| 3792 | 1 |
| 1691 | 1 |
| 1629 | 1 |
| 1622 | 1 |
| 1647 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18421171 | METHODS AND COMPOSITIONS COMPRISING A CARDIO-TOLERATED HDAC INHIBITOR | OUSPENSKI, ILIA I | 3792 | §102§112DP | Non-Final OA | — | Pending | Jan 24, 2024 |
| 18517019 | Combination Therapies Comprising Kras Inhibitors and SPH2 Inhibitors | RAO, SAVITHA M | 1691 | §103 | Non-Final OA | — | Pending | Nov 22, 2023 |
| 18351439 | COMBINATION THERAPIES OF WDR-5 INHIBITORS AND PD-1 INHIBITORS | TOWNSLEY, SARA ELIZABETH | 1629 | §103 | Final Rejection | 22d overdue | Pending | Jul 12, 2023 |
| 18120311 | MLL1-WDR5 PROTEIN-PROTEIN INTERACTION INHIBITOR COMPOUNDS AND USES THEREOF | ELENISTE, PIERRE PAUL | 1622 | §102§103Other | Final Rejection | 8d | Pending | Mar 10, 2023 |
| 16894532 | TRIPLET THERAPIES OF HDAC INHIBITORS, PD-L1 AND/OR PD-1 INHIBITORS, AND CTLA-4 INHIBITORS | BUTTICE, AUDREY L | 1647 | §103 | Final Rejection | 35d overdue | Pending | Jun 05, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialHuyabio International LLC has 5 pending office actions as of October 2026, spread across 5 art units and 5 examiners.
Ilia I Ouspenski has the most, with 1 of Huyabio International LLC's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
